Psychological and clinical factors implicated in decision making about a trial of low-dose tamoxifen in hormone replacement therapy users

Gabriella Rondanina, Matteo Puntoni, Gianluca Severi, Clara Varricchio, Anna Zunino, Irene Feroce, Bernardo Bonanni, Andrea Decensi

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Purpose: To assess the sociodemographic, health-related, and psychological factors that influence the decision of women on hormone replacement therapy (HRT) to participate in a phase III trial of low-dose tamoxifen. Patients and Methods: Clinical and psychological factors were assessed in 265 women who accepted and 192 women who refused to participate in a proposed trial. Health-related and sociodemographic factors included age, Gail risk, body mass index, education, current HRT use, regular mammographic screening, smoking habit, physical activity, alcohol use, concern about adverse effects, and physician recommendation. Psychological factors included breast cancer-related worry, absolute and comparative cancer risk perception, anxiety, and depression. Results: The most frequent reasons for entry were willingness to participate in a research program (60%), the need/desire to receive frequent medical care (58%), and the desire to contribute to medical knowledge (44%); whereas reasons for refusal included fear of medication abuse (33%), concern about adverse effects (31%), and physician advice against enrollment (24%). In a logistic model, after adjusting for current HRT use, the trial participation was directly associated with satisfaction with clearly explained study objectives (odds ratio [OR] = 9.33; 95% CI, 4.04 to 21.55) and inversely associated with high breast cancer worry (OR = 0.15; 95% CI, 0.03 to 0.77) and age ≥ 60 years (OR = 0.40; 95% CI, 0.22 to 0.73). Conclusion: Participation in a chemoprevention trial among HRT users is associated with a younger age, no breast cancer worry, and satisfaction with health care providers, suggesting a condition of psychological well-being as a promoting factor and emphasizing the importance of thorough counseling at study presentation.

Original languageEnglish
Pages (from-to)1537-1543
Number of pages7
JournalJournal of Clinical Oncology
Volume26
Issue number9
DOIs
Publication statusPublished - 2008

Fingerprint

Hormone Replacement Therapy
Tamoxifen
Decision Making
Psychology
Odds Ratio
Breast Neoplasms
Physicians
Age Factors
Chemoprevention
Health
Health Personnel
Habits
Fear
Counseling
Body Mass Index
Anxiety
Logistic Models
Smoking
Alcohols
Exercise

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Psychological and clinical factors implicated in decision making about a trial of low-dose tamoxifen in hormone replacement therapy users. / Rondanina, Gabriella; Puntoni, Matteo; Severi, Gianluca; Varricchio, Clara; Zunino, Anna; Feroce, Irene; Bonanni, Bernardo; Decensi, Andrea.

In: Journal of Clinical Oncology, Vol. 26, No. 9, 2008, p. 1537-1543.

Research output: Contribution to journalArticle

@article{4b9607be14cc40fabf6e7e4d951364fd,
title = "Psychological and clinical factors implicated in decision making about a trial of low-dose tamoxifen in hormone replacement therapy users",
abstract = "Purpose: To assess the sociodemographic, health-related, and psychological factors that influence the decision of women on hormone replacement therapy (HRT) to participate in a phase III trial of low-dose tamoxifen. Patients and Methods: Clinical and psychological factors were assessed in 265 women who accepted and 192 women who refused to participate in a proposed trial. Health-related and sociodemographic factors included age, Gail risk, body mass index, education, current HRT use, regular mammographic screening, smoking habit, physical activity, alcohol use, concern about adverse effects, and physician recommendation. Psychological factors included breast cancer-related worry, absolute and comparative cancer risk perception, anxiety, and depression. Results: The most frequent reasons for entry were willingness to participate in a research program (60{\%}), the need/desire to receive frequent medical care (58{\%}), and the desire to contribute to medical knowledge (44{\%}); whereas reasons for refusal included fear of medication abuse (33{\%}), concern about adverse effects (31{\%}), and physician advice against enrollment (24{\%}). In a logistic model, after adjusting for current HRT use, the trial participation was directly associated with satisfaction with clearly explained study objectives (odds ratio [OR] = 9.33; 95{\%} CI, 4.04 to 21.55) and inversely associated with high breast cancer worry (OR = 0.15; 95{\%} CI, 0.03 to 0.77) and age ≥ 60 years (OR = 0.40; 95{\%} CI, 0.22 to 0.73). Conclusion: Participation in a chemoprevention trial among HRT users is associated with a younger age, no breast cancer worry, and satisfaction with health care providers, suggesting a condition of psychological well-being as a promoting factor and emphasizing the importance of thorough counseling at study presentation.",
author = "Gabriella Rondanina and Matteo Puntoni and Gianluca Severi and Clara Varricchio and Anna Zunino and Irene Feroce and Bernardo Bonanni and Andrea Decensi",
year = "2008",
doi = "10.1200/JCO.2007.13.6739",
language = "English",
volume = "26",
pages = "1537--1543",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "9",

}

TY - JOUR

T1 - Psychological and clinical factors implicated in decision making about a trial of low-dose tamoxifen in hormone replacement therapy users

AU - Rondanina, Gabriella

AU - Puntoni, Matteo

AU - Severi, Gianluca

AU - Varricchio, Clara

AU - Zunino, Anna

AU - Feroce, Irene

AU - Bonanni, Bernardo

AU - Decensi, Andrea

PY - 2008

Y1 - 2008

N2 - Purpose: To assess the sociodemographic, health-related, and psychological factors that influence the decision of women on hormone replacement therapy (HRT) to participate in a phase III trial of low-dose tamoxifen. Patients and Methods: Clinical and psychological factors were assessed in 265 women who accepted and 192 women who refused to participate in a proposed trial. Health-related and sociodemographic factors included age, Gail risk, body mass index, education, current HRT use, regular mammographic screening, smoking habit, physical activity, alcohol use, concern about adverse effects, and physician recommendation. Psychological factors included breast cancer-related worry, absolute and comparative cancer risk perception, anxiety, and depression. Results: The most frequent reasons for entry were willingness to participate in a research program (60%), the need/desire to receive frequent medical care (58%), and the desire to contribute to medical knowledge (44%); whereas reasons for refusal included fear of medication abuse (33%), concern about adverse effects (31%), and physician advice against enrollment (24%). In a logistic model, after adjusting for current HRT use, the trial participation was directly associated with satisfaction with clearly explained study objectives (odds ratio [OR] = 9.33; 95% CI, 4.04 to 21.55) and inversely associated with high breast cancer worry (OR = 0.15; 95% CI, 0.03 to 0.77) and age ≥ 60 years (OR = 0.40; 95% CI, 0.22 to 0.73). Conclusion: Participation in a chemoprevention trial among HRT users is associated with a younger age, no breast cancer worry, and satisfaction with health care providers, suggesting a condition of psychological well-being as a promoting factor and emphasizing the importance of thorough counseling at study presentation.

AB - Purpose: To assess the sociodemographic, health-related, and psychological factors that influence the decision of women on hormone replacement therapy (HRT) to participate in a phase III trial of low-dose tamoxifen. Patients and Methods: Clinical and psychological factors were assessed in 265 women who accepted and 192 women who refused to participate in a proposed trial. Health-related and sociodemographic factors included age, Gail risk, body mass index, education, current HRT use, regular mammographic screening, smoking habit, physical activity, alcohol use, concern about adverse effects, and physician recommendation. Psychological factors included breast cancer-related worry, absolute and comparative cancer risk perception, anxiety, and depression. Results: The most frequent reasons for entry were willingness to participate in a research program (60%), the need/desire to receive frequent medical care (58%), and the desire to contribute to medical knowledge (44%); whereas reasons for refusal included fear of medication abuse (33%), concern about adverse effects (31%), and physician advice against enrollment (24%). In a logistic model, after adjusting for current HRT use, the trial participation was directly associated with satisfaction with clearly explained study objectives (odds ratio [OR] = 9.33; 95% CI, 4.04 to 21.55) and inversely associated with high breast cancer worry (OR = 0.15; 95% CI, 0.03 to 0.77) and age ≥ 60 years (OR = 0.40; 95% CI, 0.22 to 0.73). Conclusion: Participation in a chemoprevention trial among HRT users is associated with a younger age, no breast cancer worry, and satisfaction with health care providers, suggesting a condition of psychological well-being as a promoting factor and emphasizing the importance of thorough counseling at study presentation.

UR - http://www.scopus.com/inward/record.url?scp=41149143114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41149143114&partnerID=8YFLogxK

U2 - 10.1200/JCO.2007.13.6739

DO - 10.1200/JCO.2007.13.6739

M3 - Article

C2 - 18349406

AN - SCOPUS:41149143114

VL - 26

SP - 1537

EP - 1543

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 9

ER -